ProCE Banner Activity

FDA Pooled Analysis: Survival Outcomes With First-line Chemo-IO vs IO Alone for Treatment of Advanced NSCLC With PD-L1 Expression 1% to 49%

Slideset Download
Conference Coverage
Results of this retrospective exploratory analysis suggest that chemo-IO regimens may improve OS and PFS compared with IO alone in most patients with previously untreated advanced NSCLC and tumor PD-L1 expression 1% to 49%.

Released: June 05, 2021

Expiration: June 04, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme